



## Recent Advances in Melatonin for Cancer Therapy

Guest Editor:

**Dr. Javier Menéndez-  
Menéndez**

Department of Physiology and  
Pharmacology, School of  
Medicine, University of Cantabria,  
Santander, Spain

Deadline for manuscript  
submissions:  
**closed (20 January 2023)**

### Message from the Guest Editor

Dear Colleagues,

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized and secreted mainly by the pineal gland in the dark. In the last 20 years, multiple reports (clinical trials and in vivo and in vitro studies) have documented that the pineal hormone has many potential benefits when it is included in protocols designed to treat tumors because it modulates tumor gene expression impairing cell growth and inhibiting angiogenesis and metastasis. As melatonin has no toxicity, it deserves to be considered as an agent for use as a co-adjuvant in cancer prevention and treatment. This Special Issue aims to bring together current knowledge about melatonin targeting, delivery, and dosage form design (as controlled-release systems), and the newest findings concerning melatonin pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (interactions between melatonin and its different receptors, such as MT-1, MT-2, calmodulin, or nuclear receptors).

Dr. Javier Menéndez-Menéndez  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Ernest Mario School of  
Pharmacy, Rutgers, The State  
University of New Jersey, William  
Levine Hall, Room 225C, 160  
Frelinghuysen Road, Piscataway,  
NJ 08854-8020, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma